“At Immuneering we aim to create medicines for all patients with tumors driven by RAS mutations and other challenging MAPK pathway activation events. In our animal studies, IMM-1-104 strongly inhibited the growth of some of the most aggressive and deadly RAS mutant tumor models out there, without the need to combine with other agents and with good preclinical tolerability. Filing the IND brings us one step closer to evaluating IMM-1-104 in patients with a broad range of RAS mutant tumors,” said Ben Zeskind, Chief Executive Officer, Immuneering Corporation. “IMM-1-104 was created in-house at Immuneering, based on insights from our patented Disease Cancelling Technology. I am so incredibly proud of our world-class team of Immuneers, who worked tirelessly to move this program from concept to IND submission with exceptional speed and efficiency – an urgency befitting the strength of the preclinical data and the patients in need who are waiting. We look forward to the next steps of clinical development for IMM-1-104, and pending regulatory review of our IND, expect to enroll our first patient in the fourth quarter of this year.”
